109 search results for: patient burden
On-Treatment Clinical Remission in Asthma Patients Case Tool
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients
Expert Interview with Dr Jason Hawkes
Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.
Loss of Smell is a Key Symptom of CRSwNP
Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier describes a typical patient presentation in the pediatric asthma clinic and explores whether clinical remission is a goal of treatment for this patient and others like them.
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up
In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Leonard Bacharier revisits a patient case study where a biologic has been added to an asthma management plan and describes the potential for this patient to achieve on-therapy clinical remission.
Skin Dyspigmentation In Prurigo Nodularis (PN)
This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Partnering With Patients: Scores That Matter in CRSwNP
Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
